Liposome Company Abelcet expands anti-fungal indications with Oct. 18 sNDA approval.
Executive Summary
THE LIPOSOME COMPANY ABELCET ANTI-FUNGAL INDICATIONS BROADENED to include use against several additional types of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. The Oct. 18 approval expands Abelcet's listed indications to include candidiasis, cryptococcal meningitis, zygomycosis, and fusariosis. The company submitted the supplemental NDA in April.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth